AnTolRx, Inc.

Industry

  • Pharmaceuticals
  • Biotechnology
    • Nanotechnology, Chips, etc.
See more in Biomedtracker

Latest on AnTolRx, Inc.

In Vivo

Biopharma Quarterly Dealmaking Statistics, Q3 2016

 
• By Amanda Micklus and Maureen Riordan

Financings Third-quarter 2016 biopharma financing totaled $7.4 billion, a 54% increase over Q2’s $4.8 billion. Follow-on public offerings were again the lead financing vehicle, bringing in $3.36 billi

In Vivo

Deals Shaping the Medical Industry, October 2016

 
• By Steven Muntner, Beth Allan, Maureen Riordan, Deanna Kamienski, and Amanda Micklus

IN VITRO DIAGNOSTICS Mergers & Acquisitions Alere Inc. TechLab Inc. Pharos Capital Group has taken a controlling interest in TechLab Inc. from Alere Inc. and TechLab's founders Dr. Tracy Wilki

Scrip

Venture Funding Deals: New Cash For Delinia, Peloton, Fortis & Others

 
• By Deanna Kamienski, Beth Allan, Maureen Riordan, and Steven Muntner

Advantagene Closes $14.2m Series A Round Immuno-oncology firm Advantagene Inc. raised $14.2m through the sale of its Series A convertible preferred shares to undisclosed investors. National Securi

Scrip

Start-Up Quarterly Statistics, Q3 2016

 
• By Deanna Kamienski

Biopharma start-ups brought in half as much funding in the third quarter as in the second quarter, but the number of alliances for new and emerging therapeutics firms stayed the same. Big pharma made